Equities analysts expect that Bruker Co. (NASDAQ:BRKR) will report earnings of $0.49 per share for the current quarter, according to Zacks. Seven analysts have made estimates for Bruker’s earnings, with the lowest EPS estimate coming in at $0.47 and the highest estimate coming in at $0.50. Bruker posted earnings of $0.46 per share during the same quarter last year, which would suggest a positive year over year growth rate of 6.5%. The business is scheduled to report its next earnings results on Monday, February 12th.

On average, analysts expect that Bruker will report full year earnings of $1.19 per share for the current year, with EPS estimates ranging from $1.18 to $1.20. For the next fiscal year, analysts anticipate that the firm will report earnings of $1.34 per share, with EPS estimates ranging from $1.30 to $1.42. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Bruker.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.29 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The business had revenue of $435.60 million for the quarter, compared to analysts’ expectations of $415.45 million. Bruker had a return on equity of 25.83% and a net margin of 8.85%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.32 EPS.

BRKR has been the topic of several recent research reports. JPMorgan Chase & Co. upgraded Bruker from an “underweight” rating to a “neutral” rating and set a $28.00 target price on the stock in a report on Friday, November 3rd. Bank of America upgraded Bruker from an “underperform” rating to a “neutral” rating and set a $34.00 target price on the stock in a report on Friday, November 3rd. Cowen restated a “hold” rating and set a $29.00 target price on shares of Bruker in a report on Friday, November 3rd. Citigroup upped their price objective on Bruker from $29.00 to $34.00 and gave the company a “neutral” rating in a report on Friday, November 3rd. Finally, Zacks Investment Research upgraded Bruker from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a report on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and five have issued a buy rating to the company’s stock. Bruker presently has an average rating of “Hold” and a consensus price target of $32.38.

Large investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in Bruker during the second quarter worth $111,000. Zions Bancorporation acquired a new position in Bruker during the third quarter worth $119,000. Bank of Montreal Can lifted its stake in Bruker by 346.7% during the fourth quarter. Bank of Montreal Can now owns 3,708 shares of the medical research company’s stock worth $128,000 after purchasing an additional 2,878 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Bruker by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after purchasing an additional 331 shares in the last quarter. Finally, Advisory Services Network LLC lifted its stake in Bruker by 6.3% during the second quarter. Advisory Services Network LLC now owns 6,847 shares of the medical research company’s stock worth $197,000 after purchasing an additional 406 shares in the last quarter. Institutional investors own 65.60% of the company’s stock.

Bruker (BRKR) opened at $35.57 on Thursday. The firm has a market capitalization of $5,508.48, a P/E ratio of 37.84, a PEG ratio of 2.62 and a beta of 1.12. Bruker has a twelve month low of $21.83 and a twelve month high of $36.53. The company has a current ratio of 2.60, a quick ratio of 1.60 and a debt-to-equity ratio of 0.65.

WARNING: “” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/01/28/1584164.html.

About Bruker

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Get a free copy of the Zacks research report on Bruker (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bruker (NASDAQ:BRKR)

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply